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Introduction
Herein we report a case of inflamed actinic keratoses 
(AKs) in a patient with NSCLC after receiving 
combination therapy with pemetrexed and 
carboplatin.
Case Synopsis
A 68-year-old woman with a two-month history 
of biopsy-confirmed stage IIIA NSCLC, pT3N1, 
status-post bilobectomy, presented with a rash on 
her upper chest, upper back, and arms bilaterally 
(Figure 1) on day 13 after completing the first cycle 
of combination chemotherapy with carboplatin 
(474mg) and pemetrexed (950mg). She denied 
any other new medications, supplements, or 
environmental exposures. The rash was described 
as having a red, pruritic, and mild “burning/stinging” 
quality and worsened with exposure to sunlight. In 
addition to a standard three-day prophylactic course 
of dexamethasone from days 1-3, the patient was 
taking 25mg of diphenhydramine and applying over 
Abstract
Eruptive actinic keratosis (AK) consequent to systemic 
chemotherapy can be confused with drug allergies. 
We present the first case of inflamed AKs in one patient 
after receiving combination therapy with pemetrexed 
and carboplatin.
A 68-year-old woman with non-small cell lung 
adenocarcinoma (NSCLC) presented with numerous 
pruritic ill-defined, gritty, erythematous papules 
consistent with AKs on her upper chest, upper 
back, and arms two weeks after completing the 
first cycle of combination therapy with carboplatin 
and pemetrexed. The care team managed her with 
topical steroids and the lesions resolved within one 
month. The patient resumed the second cycle of 
chemotherapy and reported the occurrence of a 
similar but milder eruption.
This case illustrates that eruptive AKs should be 
considered in the differential diagnosis of drug-related 
rashes, especially if the physical exam is suggestive. 
The mainstay of treatment should be directed at 
symptomatic improvement, and chemotherapy may 
be continued.
Figure 1. Broad view of upper chest.
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the counter diphenhydramine-hydrocortisone cream 
as needed on days 13-14 with no improvement. 
Her oncologist saw her on day 20 and prescribed 
dexamethasone 4mg twice per day for the eruption. 
The oncologist also decided to delay initiation of 
cycle 2 of the patient’s chemotherapy (typically given 
every three weeks) until further evaluation was made 
by the dermatology department. When the patient 
was seen at the dermatology clinic on day 24, the 
patient reported that while the rash was still present, 
it was not as red or symptomatic as it was initially. 
She denied any fever, facial or acral swelling, mucosal 
involvement (eyes, mouth, genital), bleeding, malaise, 
or difficulty breathing or swallowing. On physical 
exam, numerous ill-defined, gritty, thin, distinct, 
erythematous, blanchable papules were present 
on the upper chest, upper back, dorsal arms, and 
distal lower extremities over background changes of 
chronic photodamage (Figure 2).
Based on the distribution of the eruption in sun-
exposed areas and the characteristic physical exam 
findings, the diagnosis of inflammatory, eruptive AKs 
was made. We postulated that the lesions resulted 
from a reactive inflammatory response to systemic 
chemotherapy from pemetrexed and carboplatin. 
The patient was started on triamcinolone 0.1% 
ointment twice per day to the lesions. Flaring of the 
rash, to a much lesser degree, was reported with the 
second cycle of chemotherapy.
Case Discussion
AKs represent dysplastic growths of keratinocytes from 
cumulative UV-induced DNA damage. Underlying 
nuclear atypia provides a permissive environment 
for the action of antineoplastic agents. Reactive 
AKs secondary to systemic chemotherapy is not 
unusual and there exists numerous case records that 
implicate the following agents: carboplatin, erlotinib, 
doxorubicin, docetaxel, capecitibine, vincristine, and 
fluorouracil [1]. The earliest incidental finding of this 
phenomenon was with systemic fluorouracil (5-FU) 
therapy [2] and formed the basis for modern topical 
5-FU therapy for multiple AKs. Pemetrexed (trade 
name, Alimta®) is a folate antimetabolite that inhibits 
multiple folate-requiring enzymes involved in 
purine and pyrimidine synthesis; it primarily targets 
thymidylate synthetase [3], thereby blocking the 
conversion of uridine monophosphate to thymidine 
monophosphate. Coincidentally, pemetrexed is 
functionally similar to 5-FU, as both agents target 
thymidylate synthetase [2, 3]. Although the exact 
mechanism of pemetrexed-associated inflammation 
of AKs is unknown, it is possibly similar to 5-FU. It is 
not clear how the carboplatin may have additionally 
contributed to the patient’s response.
One potential adverse reaction to pemetrexed is 
the development of a rash. The most commonly 
reported cutaneous adverse reactions to pemetrexed 
are radiation recall dermatitis, alopecia, urticarial 
vasculitis, acute generalized exanthematous 
pustulosis, and pityriasis lichenoides [4]. Rashes were 
reported in 2% of patients taking pemetrexed as a 
single agent for NSCLC, stage IIIb and IV, in a phase 
III double-blind randomized control trial (RCT), [5]. 
Medication related eruptions are even more common 
with combination therapy. Indeed, 7.5% of patients 
developed a rash in a similar phase III RCT involving 
pemetrexed and carboplatin [6]. In both studies, 
patients were given prophylactic therapy with oral 
dexamethasone 4mg twice daily the day before, the 
day of, and the day after initiation of pemetrexed, as 
instructed by manufacturers, to prevent pemetrexed-
associated rashes [7].
It is important for clinicians to be able to distinguish 
inflamed AKs from more serious drug eruptions to 
avoid delay or cessation of life-saving medication 
administration. Accordingly, it is prudent to note 
that the reported cases of chemotherapy-induced 
Figure 2. Close-up view of primary lesions on a background of 
actinic damage located on upper chest.
Volume 23 Number 10 | October 2017 
DOJ 23 (10): 18
- 3 - 
Dermatology Online Journal  ||  Letter
inflammatory AKs thus far exhibit a characteristic 
AK appearance in a photodistribution. Moreover, 
inflamed AKs consequent to chemotherapeutic 
agents typically originate in pre-existing AKs. 
However, subclinical AKs may not be visually evident 
prior to the onset of chemotherapy-induced flaring, 
as in our patient.
Management of inflamed AKs involves topical 
corticosteroids and anti-histamines for symptomatic 
relief. Biopsy is not necessary unless ruling out allergic 
or toxic reaction. The general consensus is that 
chemotherapy may be continued [8]. For pemetrexed-
associated rashes, drug manufacturers recommend 
prophylactic therapy with dexamethasone during 
the initiation of therapy to reduce the incidence 
and severity [7]. Onset and resolution of medication 
eruptions vary widely with the individual, lasting from 
weeks to months [9]. In this particular case, onset 
occurred approximately two weeks after initiation of 
chemotherapy and was almost completely resolved 
in one month, prior to flaring with the subsequent 
chemotherapy cycle.
To our knowledge, there is one case report of 
pemetrexed-associated inflamed AKs and there are 
other reports of inflamed AKs from combination 
therapy involving carboplatin [10, 11, 12]. However, 
to our knowledge, there are no reports of inflamed 
AKs specifically associated with pemetrexed and 
carboplatin combination therapy.
Conclusion
It is difficult to determine whether pemetrexed, 
carboplatin, or both may have induced the 
inflamed AKs. Pemetrexed and carboplatin may 
work synergistically in mounting this inflammatory 
response. It is generally accepted that patients 
should continue chemotherapy despite reactive AKs 
and treatment of reactive AKs should be aimed at 
symptomatic improvement.
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